Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif

被引:49
作者
Di Matteo, P
Curnis, F
Longhi, R
Colombo, G
Sacchi, A
Crippa, L
Protti, MP
Ponzoni, M
Toma, S
Corti, A
机构
[1] San Raffaele Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy
[2] G Gaslini Childrens Hosp, Lab Oncol, Genoa, Italy
关键词
tumor necrosis factor; tumor targeting; aminopeptidase N/CD13; vascular targeting; NGR motif; NGR-TNF; molecular dynamics; fibronectin;
D O I
10.1016/j.molimm.2005.10.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor homing peptides containing the NGR motif, such as CNGRC and GNGRG, have been used for delivering cytokines, chemotherapeutic drugs, apoptotic peptides, and liposomes to a CD13 isoform expressed in tumor blood vessels. In view of the potential clinical applications of these drugs and considering the risk that NGR peptides could elicit blocking antibodies we have investigated the immunogenic properties of CNGRC and GNGRG in mice and rabbits, using various products containing these residues and different administration schedules. The results suggest that the immunogenicity of the NGR motif is very low, even when it is conjugated to tumor necrosis factor-alpha or to highly immunogenic carrier proteins. Molecular dynamics simulation experiments showed that both peptides have a strong propensity to populate a turn conformation. Superposition of predicted structures to the CTGNGRGEWKC loop of the 5th type I repeat of human fibronectin, a protein that contains four NGR motives, showed that the root mean square deviation of backbones was 0.7 angstrom for GNGRG and 0.5 angstrom for NGR. These results suggest that NGR peptides could mimic from an immunological point of view a "self" structure, likely the GNGRG loop of fibronectin, with important implications for the use of these targeting peptides in patients. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1509 / 1518
页数:10
相关论文
共 33 条
[1]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[2]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[3]   INDUCTION OF FIBRONECTIN GENE-TRANSCRIPTION AND MESSENGER-RNA IS A PRIMARY RESPONSE TO GROWTH-FACTOR STIMULATION OF AKR-2B CELLS [J].
BLATTI, SP ;
FOSTER, DN ;
RANGANATHAN, G ;
MOSES, HL ;
GETZ, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (04) :1119-1123
[4]   Strategies for vascular targeting in tumors [J].
Brekken, RA ;
Li, CG ;
Kumar, S .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (02) :123-130
[5]   VASCULAR TARGETING - A NEW APPROACH TO THE THERAPY OF SOLID TUMORS [J].
BURROWS, FJ ;
THORPE, PE .
PHARMACOLOGY & THERAPEUTICS, 1994, 64 (01) :155-174
[6]   Antibody humanization: a case of the 'Emperor's new clothes'? [J].
Clark, M .
IMMUNOLOGY TODAY, 2000, 21 (08) :397-402
[7]   Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif [J].
Colombo, G ;
Curnis, F ;
De Mori, GMS ;
Gasparri, A ;
Longoni, C ;
Sacchi, A ;
Longhi, R ;
Corti, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (49) :47891-47897
[8]   Tumor vascular targeting with tumor necrosis factor α and chemotherapeutic drugs [J].
Corti, A ;
Ponzoni, M .
SIGNAL TRANSDUCTION AND COMMUNICATION IN CANCER CELLS, 2004, 1028 :104-112
[9]  
Corti Angelo, 2004, Methods Mol Med, V98, P247
[10]   Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) [J].
Curnis, F ;
Sacchi, A ;
Borgna, L ;
Magni, F ;
Gasparri, A ;
Corti, A .
NATURE BIOTECHNOLOGY, 2000, 18 (11) :1185-1190